The European Medicines Agency is re-evaluating aliskiren-containing medicines, antihypertensives that are authorised in Belgium under the name RASILEZ and RASILEZ HCT, following termination of a clinical study in which aliskiren was used in diabetic patients in combination with another antihypertensive medicine (an angiotensin converting enzyme inhibitor or a sartan). Whilst waiting for the results of this review doctors are advised not to prescribe aliskiren to diabetic patients already treated with the above-mentioned antihypertensive medicine.
See more information on the EMA website.
Contact: vig@fagg-afmps.be